Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

Fate Therapeutics (FATE) Misses Q4 EPS by 1c, Revenues Miss

March 5, 2019 4:26 PM EST

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1.66 million versus the consensus estimate of $2.89 million.

We achieved an unprecedented milestone in treating the first patient with FT500, which is the first-ever... More